Cargando…

Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review

Rationale: Whether pharmacological therapy alters decline in FEV(1) in chronic obstructive pulmonary disease remains controversial. Because pharmacotherapy improves health status, exacerbation rate, and symptoms, it may be unethical to complete placebo-controlled long-term studies aimed at modifying...

Descripción completa

Detalles Bibliográficos
Autores principales:	Celli, Bartolome R., Anderson, Julie A., Cowans, Nicholas J., Crim, Courtney, Hartley, Benjamin F., Martinez, Fernando J., Morris, Andrea N., Quasny, Holly, Yates, Julie, Vestbo, Jørgen, Calverley, Peter M. A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7958521/ https://www.ncbi.nlm.nih.gov/pubmed/32966751 http://dx.doi.org/10.1164/rccm.202005-1854OC

Ejemplares similares

International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials
por: Calverley, Peter M. A., et al.
Publicado: (2022)

Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial
por: Byrd, James Brian, et al.
Publicado: (2018)

Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease
por: Adamson, Philip D., et al.
Publicado: (2018)

Impact of pre-enrolment medication use on clinical outcomes in SUMMIT
por: Vestbo, Jørgen, et al.
Publicado: (2019)

Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial
por: Celli, Bartolome R, et al.
Publicado: (2019)

FEV(1) is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease
por: Bikov, Andras, et al.
Publicado: (2020)

Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial
por: Brigham, Emily P., et al.
Publicado: (2021)

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk
por: Brook, Robert D, et al.
Publicado: (2017)

Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study
por: Jenkins, Christine R, et al.
Publicado: (2009)

Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial
por: Wise, Robert A, et al.
Publicado: (2020)

Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD
por: Fawzy, Ashraf, et al.
Publicado: (2019)

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change
por: Jones, Paul W, et al.
Publicado: (2011)

The severity of airways obstruction as a determinant of treatment response in COPD
por: Calverley, Peter MA, et al.
Publicado: (2006)

Reply to Fisk and Wilkinson: Aortic Pulse Wave Velocity Predicts All-Cause Mortality in Chronic Obstructive Pulmonary Disease
por: Crim, Courtney, et al.
Publicado: (2020)

Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort
por: Celli, Bartolome, et al.
Publicado: (2021)

Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype
por: Agustí, Alvar, et al.
Publicado: (2012)

A Genome-wide analysis of the response to inhaled beta2-agonists in Chronic Obstructive Pulmonary Disease
por: Hardin, Megan, et al.
Publicado: (2015)

Characterisation of COPD heterogeneity in the ECLIPSE cohort
por: Agusti, Alvar, et al.
Publicado: (2010)

Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis
por: Scott, David A, et al.
Publicado: (2015)

Influencing the decline of lung function in COPD: use of pharmacotherapy
por: Gladysheva, Ekaterina S, et al.
Publicado: (2010)

Fixed Triple Therapy in Chronic Obstructive Pulmonary Disease and Survival. Living Better, Longer, or Both?
por: Vestbo, Jørgen
Publicado: (2020)

From Laënnec’s Stethoscope to the Magic of Imaging, Big Data and Artificial Intelligence: A Timeline of Precision Medicine for Patients with Chronic Obstructive Pulmonary Disease
por: Celli, Bartolome
Publicado: (2023)

Mortality after admission with pneumonia is higher than after admission with an exacerbation of COPD
por: Vestbo, Jørgen, et al.
Publicado: (2022)

New Perspectives on Chronic Obstructive Pulmonary Disease
por: Celli, Bartolome R, et al.
Publicado: (2022)

Factors associated with change in exacerbation frequency in COPD
por: Donaldson, Gavin C, et al.
Publicado: (2013)

Adverse health consequences in COPD patients with rapid decline in FEV(1 )- evidence from the UPLIFT trial
por: Kesten, Steven, et al.
Publicado: (2011)

Pharmacotherapy for Chronic Obstructive Pulmonary Disease: Molecules and Delivery Are Equally Important
por: Mahler, Donald A., et al.
Publicado: (2020)

Rapid decline in lung function in healthy adults predicts incident excess urinary albumin excretion later in life
por: Bhatia, Sapna, et al.
Publicado: (2017)

Biomarkers of systemic inflammation and depression and fatigue in moderate clinically stable COPD
por: Al-shair, Khaled, et al.
Publicado: (2011)

The Role of Animal Models in Developing Pharmacotherapy for Obstructive Sleep Apnea
por: Kim, Lenise Jihe, et al.
Publicado: (2019)

The Management of Severe Chronic Obstructive Pulmonary Disease
por: Calverley, Peter M A
Publicado: (1999)

Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis
por: Mills, Edward J, et al.
Publicado: (2011)

Defining Airflow Obstruction: More Data, Further Clarity
por: Calverley, Peter M. A.
Publicado: (2020)

Observational studies assessing the pharmacological treatment of obstructive lung disease: strengths, challenges and considerations for study design
por: Vestbo, Jørgen, et al.
Publicado: (2020)

Role of Appetite-Regulating Peptides in the Pathophysiology of Addiction: Implications for Pharmacotherapy
por: Engel, Jörgen A., et al.
Publicado: (2014)

Major Publications in the Critical Care Pharmacotherapy Literature: 2020
por: Bissell, Brittany D., et al.
Publicado: (2021)

Reply to Pouwels et al.: Confounding Factors Affecting sRAGE as a Biomarker for Chronic Obstructive Pulmonary Disease
por: Stockley, Robert A., et al.
Publicado: (2019)

Guidance for the Better Care of Patients with Chronic Obstructive Pulmonary Disease
por: Calverley, Peter M. A.
Publicado: (2020)

Reply to Kawada: Obstructive Sleep Apnea and Cognitive Decline in Older Adults
por: Baril, Andrée-Ann, et al.
Publicado: (2019)

Pharmacotherapy in COVID 19: Potential Impact of Targeting the Complement System
por: Barkoff, Courtney M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_71fpi3v99ms7j5fffhb4fue3d5